Myocardial Infarction

Celera identifies genetic polymorphism associated with increased risk for myocardial infarction

Published in Gene Therapy Weekly, October 26th, 2006

Celera Genomics (CRA), an Applera Corporation business, announced a publication describing a genetic polymorphism in the gene encoding the myeloid IgA Fc receptor, the FCAR Asp92Asn polymorphism, associated with increased risk for myocardial infarction (MI) and coronary heart disease (CHD).

These results were obtained in genetic studies of two separate prospective randomized clinical trials assessing the effect of pravastatin on prevention of MI and CHD: the Cholesterol and Recurrent Events study (CARE) and West of Scotland Coronary Prevention Study (WOSCOPS). The risk of coronary events associated with the FCAR Asp92Asn polymorphism in both CARE and WOSCOPS was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-10-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry